Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$20.2MCash on Hand
9.2mo Cash Runway
Follow PASG by emailGet an email when PASG reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PASG, unsubscribe in one click. Privacy
📣 What PASG Says Is Next
1Q 2027 · “Advancing clinical stage, potential best-in-class, one-time progranulin raising gene therapy for FTD Pursuing preclinical development of differentiated gene therapy approach in Huntington’s disease Cash runway expected through 1Q 2027* Validating the Therapeutic Potential of PBFT02 4 April 2026 * Based on interim data.”
Company press release, Apr 20, 2026 · SEC filing
1Q 2027 · “Advancing clinical stage, potential best-in-class, one-time progranulin raising gene therapy for FTD Pursuing preclinical development of differentiated gene therapy approach in Huntington’s disease Cash runway expected through 1Q 2027* Validating the Therapeutic Potential of PBFT02 4 March 2026 * Based on interim data.”
Company press release, Mar 3, 2026 · SEC filing
1Q 2027 · “Advancing clinical stage, potential best - in - class, one - time progranulin raising gene therapy for FTD Pursuing preclinical development of differentiated gene therapy approach in Huntington’s disease Cash runway expected into 1Q 2027* Validating the Therapeutic Potential of PBFT02 January 2026 4 * Based on interim data.”
Company press release, Jan 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 6, 2026 ·
Shareholder vote Stockholders of Passage Bio approved the Remix 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan at a November 5, 2026 special meeting, both contingent on the completion of the First Merger. The 2026 Plan reserves 5,772,500 shares plus carried-over shares. Form 8-K · SEC filing
Sep 3, 2026 ·
Deal Passage Bio and Remix Therapeutics amended and restated their merger agreement on Sept 2, 2026, adding a two-step merger structure and pre-funded warrants in the concurrent financing. Economic terms and the Dec 24, 2026 outside date are unchanged. Form 8-K · SEC filing
Aug 10, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PASG holds $20.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.6M/quarter from operations,
an estimated runway of 9.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 9 months +30
ATM program on file since Mar 2025 +15
Shelf registration (S-3, Mar 2024) +10
Going-concern doubt in the latest 10-Q +15As a result, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.10-Q, Nov 2026
Share count 3,217,810 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PASG picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PASG and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.